☰

Habib R. Hamidi, Ph.D. - Publications

Affiliations: 
2009 University of California, Los Angeles, Los Angeles, CA 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF, Leng N, Abbas AR, Fan J, Koeppen H, Lin J, Carroll S, Hashimoto K, et al. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell. PMID 33157048 DOI: 10.1016/j.ccell.2020.10.011  0.32
2020 Schaub JA, Hamidi H, Subramanian L, Kretzler M. Systems Biology and Kidney Disease. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 31992571 DOI: 10.2215/Cjn.09990819  0.304
2016 Way GP, Rudd J, Wang C, Hamidi H, Fridley BL, Konecny GE, Goode EL, Greene CS, Doherty JA. Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes. G3 (Bethesda, Md.). PMID 27729437 DOI: 10.1534/G3.116.033514  0.36
2016 Winterhoff B, Hamidi H, Wang C, Kalli KR, Fridley BL, Dering J, Chen HW, Cliby WA, Wang HJ, Dowdy S, Gostout BS, Keeney GL, Goode EL, Konecny GE. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. Gynecologic Oncology. 141: 95-100. PMID 27016234 DOI: 10.1016/J.Ygyno.2016.02.023  0.389
2015 He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, Palmer JS, Roche DK, Hollier BG, Westbrook TF, Hamidi H, Konecny GE, Winterhoff B, Chetty NP, Crandon AJ, et al. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene. PMID 25893298 DOI: 10.1038/Onc.2015.101  0.387
2015 Drew BG, Hamidi H, Zhou Z, Villanueva CJ, Krum SA, Calkin AC, Parks BW, Ribas V, Kalajian NY, Phun J, Daraei P, Christofk HR, Hewitt SC, Korach KS, Tontonoz P, et al. Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression. The Journal of Biological Chemistry. 290: 5566-81. PMID 25468909 DOI: 10.1074/Jbc.M114.606459  0.336
2014 Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. Journal of the National Cancer Institute. 106. PMID 25269487 DOI: 10.1093/Jnci/Dju249  0.353
2014 Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, Linnartz R, Zubel A, Slamon DJ, Finn RS. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. British Journal of Cancer. 111: 1788-801. PMID 25167228 DOI: 10.1038/Bjc.2014.475  0.346
2014 Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, Winterhoff BJ, Hamidi H, Konecny GE, Chien J, Bibikova M, et al. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Scientific Reports. 4: 4026. PMID 24504028 DOI: 10.1038/Srep04026  0.34
2014 Wong DJ, Garon EB, Silveira DD, Kamranpour N, Pitts S, Chalukya M, Hamidi H, Dubinett S, Linnartz R, Finn RS, Slamon DJ. Abstract 743: Potent anti-tumor activity of the MEK1/2 inhibitor MEK162 in human non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN) cell lines Cancer Research. 74: 743-743. DOI: 10.1158/1538-7445.Am2014-743  0.402
2013 Mostofizadeh N, Desai AJ, Von Euw EM, Conklin D, Konkatkit V, Hamidi H, Eckardt MA, Anderson L, Cheng HW, Ginther C, Taschereau E, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF. Effect of PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, on proliferation in renal cell carcinoma at nanomolar concentrations and prediction of sensitivity by molecular markers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 413. PMID 28137146 DOI: 10.1200/Jco.2013.31.6_Suppl.413  0.31
2013 Cicek MS, Koestler DC, Fridley BL, Kalli KR, Armasu SM, Larson MC, Wang C, Winham SJ, Vierkant RA, Rider DN, Block MS, Klotzle B, Konecny G, Winterhoff BJ, Hamidi H, et al. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Human Molecular Genetics. 22: 3038-47. PMID 23571109 DOI: 10.1093/Hmg/Ddt160  0.402
2013 Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Molecular Cancer Therapeutics. 12: 890-900. PMID 23493311 DOI: 10.1158/1535-7163.Mct-12-0998  0.376
2013 Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG. Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab Plos One. 8. PMID 23405260 DOI: 10.1371/Journal.Pone.0056112  0.335
2013 Konecny GE, Wang C, Winterhoff B, Dering J, Ginther C, Chen H, Hamidi H, Podratz KC, Cliby W, Dowdy SC, Haluska P, Hartmann LC, Kalli K, Goode EL, Slamon DJ. Prognostic relevance of gene signatures in high-grade serous ovarian carcinoma. Journal of Clinical Oncology. 31: 5510-5510. DOI: 10.1200/Jco.2013.31.15_Suppl.5510  0.443
2013 Hamidi HR, Finn R, Anderson L, Lu M, Fejzo M, Ginther C, Linnartz R, Zubel A. Abstract 936: KRAS mutational subtypes and copy number variations are predictive of response of human pancreatic cancer cell lines to MEK162in vitro. Cancer Research. 73: 936-936. DOI: 10.1158/1538-7445.Am2013-936  0.387
2013 Logan J, Mostofizadeh N, Desai A, Euw Ev, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen H, Ginther C, Taschereau E, Christensen J, Belldegrun A, Slamon D, et al. 612 Pd-0332991, An Inhibitor Of Cyclin-Dependent Kinase 4/6, Demonstrates Inhibition Of Proliferation In Renal Cell Carcinoma At Nanomolar Concentrations And Molecular Markers Predict For Sensitivity The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.163  0.312
2011 Eradat HA, Eckardt MA, Dorfman E, Hamidi H, Ginther C, Finn RS, Los G, Christensen JG, De Vos S, Slamon DJ. Cell cycle effects of CDK 4/6 inhibitor PD 0332991 in diffuse large B-cell lymphoma cell lines in vitro. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8061. PMID 28023509 DOI: 10.1200/Jco.2011.29.15_Suppl.8061  0.327
2011 Hamidi H, Gustafason D, Pellegrini M, Gasson J. Identification of novel targets of CSL-dependent Notch signaling in hematopoiesis. Plos One. 6. PMID 21637838 DOI: 10.1371/Journal.Pone.0020022  0.508
2009 Vega VB, Woo XY, Hamidi H, Yeo HC, Yeo ZX, Bourque G, Clarke ND. Inferring direct regulatory targets of a transcription factor in the DREAM2 challenge. Annals of the New York Academy of Sciences. 1158: 215-23. PMID 19348643 DOI: 10.1111/J.1749-6632.2008.03759.X  0.363
Show low-probability matches.